Carboplatin Alone vs Carboplatin plus Epidoxorubicin as Second-Line Therapy for Cisplatin- or Carboplatin-Sensitive Ovarian Cancer

By Bolis G.   Scarfone G.   Giardina G.   Villa A.   Mangili G.   Melpignano M.   Presti M.   Tateo S.   Franchi M.   Parazzini F.   on behalf of the Associazione per la Ricerca in Ginecologia Oncologica ARGO 96 Study Group  

Gynecologic Oncology, Vol. 81, Iss. 1, 2001-04 ,pp. : 3-9

Elsevier

Access to resources Recommend Favorite

Platinum-Resistant and Refractory Ovarian Cancer: Second-Line Treatment Options

By Alvarez A.A.   Clarke-Pearson D.L.  

American Journal of Cancer, Vol. 2, Iss. 1, 2003-01 ,pp. : 1-13

Adis International

Access to resources Recommend Favorite

Second-Line Therapy of Ovarian Cancer with Paclitaxel Administered by Both the Intravenous and Intraperitoneal Routes: Rationale and Case Reports

By Markman M.   Kulp B.   Peterson G.   Kennedy A.   Belinson J.  

Gynecologic Oncology, Vol. 86, Iss. 1, 2002-07 ,pp. : 95-98

Academic Press

Access to resources Recommend Favorite

Topotecan in Platinum- and Paclitaxel-Resistant Ovarian Cancer

By Swisher E.M.   Mutch D.G.   Rader J.S.   Elbendary A.   Herzog T.J.  

Gynecologic Oncology, Vol. 66, Iss. 3, 1997-09 ,pp. : 480-486

Elsevier

Access to resources Recommend Favorite

First-line chemotherapy with epidoxorubicin, paclitaxel, and carboplatin for the treatment of advanced epithelial ovarian cancer patients

By Romanini A.   Tanganelli L.   Carnino F.   Fanucchi A.   Lionetto R.   Pastorino S.   Cosio S.   Gadducci A.   Conte P.F.  

Gynecologic Oncology, Vol. 89, Iss. 3, 2003-06 ,pp. : 354-359

Elsevier

Access to resources Recommend Favorite